U.S. Markets closed

Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells

PCM-075 enhances activity of abiraterone in mCRPC tumors cells and may represent a novel treatment option to extend the benefit of anti-androgen therapy

SAN DIEGO, Oct. 18, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced positive data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective Polo-like Kinase 1 (PLK1) Inhibitor, in combination with abiraterone (Zytiga® - Johnson & Johnson). Abiraterone is a potent and irreversible inhibitor of CYP17, a critical enzyme in androgen biosynthesis and is indicated for the treatment of mCRPC in combination with prednisone. This research was performed in collaboration with a major cancer research institution.

A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease. (PRNewsFoto/Trovagene, Inc.)

"The synergy observed when we combined PCM-075 with abiraterone appears to work through a novel mechanism that may modulate a signaling pathway previously unknown to be associated with this combination," said Dr. Mark Erlander, Chief Scientific Officer of Trovagene. "This unique combination appears to enhance the PCM-075 mechanism of action of arresting cells during mitosis with subsequent tumor cell death."

Metastatic Prostate Cancer is the third leading cause of cancer death in men. Approximately 25,000 men progress to metastatic Castration-Resistant Prostate Cancer (mCRPC) annually and receive anti-androgen therapy with a mean progression-free survival of less than two years. Abiraterone is the leading global anti-androgen therapy, marketed by Centocor Ortho Biotech, Inc., a member of the Johnson & Johnson family of companies, with 2016 sales in excess of $2.0 billion. Even with the broad adoption of abiraterone there continues to be a large medical need to extend the benefit of response to abiraterone in mCRPC.

"We are encouraged by the preclinical data of PCM-075 in mCRPC," said Bill Welch, Chief Executive Officer of Trovagene. "We previously completed a Phase 1 trial in metastatic solid tumor cancers, which provided a recommended Phase 2 dose and dosing schedule for PCM-075 in a combination regimen.  We are working closely with key investigators to develop a Phase 2 clinical trial protocol with oral dosing of PCM-075 and abiraterone utilizing our existing solid tumor IND."

About PCM-075

PCM-075 is a highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in multiple hematologic and solid tumor cancers. Studies have shown that inhibition of polo-like-kinases can lead to tumor cell death, including a Phase 2 study in Acute Myeloid Leukemia (AML) where response rates up to 31% were observed when used in conjunction with a standard therapy for AML (low-dose cytarabine-LDAC) versus treatment with LDAC alone with a 13.3% response rate. A Phase 1 open-label, dose escalation safety study of PCM-075 has been completed in patients with advanced metastatic solid tumor cancers, and published in Investigational New Drugs. Trovagene is initiating a Phase 1b/2 clinical trial with PCM-075 in AML that was accepted by the National Library of Medicine (NLM) and is now publicly viewable on www.clinicaltrials.gov. The NCT number assigned by clinicaltrials.gov for this study is NCT03303339. PCM-075 has been granted Orphan Drug Designation by the FDA for the treatment of patients with AML.

PCM-075 only targets PLK1 isoform (not PLK2 or PLK3), is oral, has a 24-hour drug half-life with reversible on-target hematologic toxicities. Trovagene believes that targeting only PLK1 with reversible on-target activity and an improved dose/scheduling protocol can significantly improve on the long-term outcome observed in previous studies with a PLK inhibitor in AML.

PCM-075 has demonstrated synergy in preclinical studies with over 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including FLT3 and HDAC inhibitors, taxanes, and cytotoxins. Trovagene believes the combination of its targeted PLK-1 inhibitor, PCM-075, with other compounds has the potential for improved clinical efficacy in Acute Myeloid Leukemia (AML), Castration-Resistant Prostate Cancer (CRPC), Non-Hodgkin Lymphoma (NHL), Triple Negative Breast Cancer (TNBC) and Adrenocortical Carcinoma (ACC).

About Castration-Resistant Prostate Cancer (CRPC)

Castration-Resistant Prostate Cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy (ADT) and may present as one or any combination of a continuous rise in serum levels of prostate-specific antigen (PSA), progression of pre-existing disease, or appearance of new metastases. Prognosis is associated with several factors, including performance status, presence of bone pain, extent of disease on bone scan, and serum levels of alkaline phosphatase. Bone metastases will occur in 90% of men with CPRC and can produce significant morbidity, including pain, pathologic fractures, spinal cord compression, and bone marrow failure. Paraneoplastic effects are also common, including anemia, weight loss, fatigue, hypercoagulability, and increased susceptibility to infection. Institution of treatment and the choice of systemic or local therapy depend on a number of factors.

About Trovagene, Inc.

Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit https://www.trovagene.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially.  There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements.  These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.  There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovagene's strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes.  Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2016, and other periodic reports filed with the Securities and Exchange Commission.  While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties.  Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.  Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Trovagene Contact:
Vicki Kelemen
VP, Corporate Communications
858-952-7652
vkelemen@trovagene.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/trovagenes-plk1-inhibitor-pcm-075-demonstrates-synergy-with-zytiga-abiraterone-acetate-in-castration-resistant-prostate-cancer-tumor-cells-300538611.html

  • 3 Cryptocurrencies That Could Still Double
    Business
    Motley Fool

    3 Cryptocurrencies That Could Still Double

    What we as investors witnessed from cryptocurrencies last year is something that may not be duplicated again. A single asset class gained more than 3,300% in market cap (almost $600 billion) over a span of just 12 months. After beginning January on a high note, cryptocurrencies fell off a cliff, losing 67% of their market cap, from peak to trough, between Jan. 7 and Feb. 6.

  • Silicon Valley is so expensive that even Facebook and Apple employees can't afford to live near the office
    Business
    Business Insider

    Silicon Valley is so expensive that even Facebook and Apple employees can't afford to live near the office

    Silicon Valley's housing crisis is serious. A new report from Open Listings reveals that workers at five major tech companies, including Apple, Facebook, and Google, would have to spend over 28% of their salary to pay a monthly mortgage on a home near work. Software engineers at Apple have it worst.

  • Russian Olympian Who Wore an 'I Don't Do Doping' Slogan Shirt Just Failed Her Drug Test
    World
    Time

    Russian Olympian Who Wore an 'I Don't Do Doping' Slogan Shirt Just Failed Her Drug Test

    Nadezhda Sergeeva, pilot of the two-woman bobsled team representing the Olympic Athletes from Russia, proudly proclaimed her anti-doping stance when she appeared in a YouTube video wearing a sweatshirt with the slogan “I don’t do doping” stamped brightly across the front. The federation says that the bobsledder does not have a prescription for the drug.

  • Buffett says Berkshire can handle $400 billion mega-catastrophe
    Finance
    Reuters

    Buffett says Berkshire can handle $400 billion mega-catastrophe

    Warren Buffett says: Bring it on. In his annual letter to shareholders of Berkshire Hathaway Inc , Buffett said "no company comes close" to his conglomerate in its ability to financially withstand even a mega-catastrophe that causes $400 billion of insurance losses. Buffett said the odds of such a catastrophe in any year is just 2 percent, but that Berkshire would lose only about $12 billion, a sum more than offset by annual profits from its non-insurance businesses.

  • American in Custody After Severed Head Is Found in Japan
    News
    Time

    American in Custody After Severed Head Is Found in Japan

    An American man is in custody in Japan after authorities found a severed head in a suitcase left in a lodging facility. Japanese investigators said the 26-year-old American was seen on security footage with a 27-year-old woman who went missing, The Japan Times reported. Police were investigating the woman’s disappearance when they came upon what appears to be her missing head, still inside a suitcase in an Osaka lodging facility, they said.

  • Bitcoin Cash, Litecoin and Ripple Daily Analysis – 25/02/18
    Business
    FX Empire

    Bitcoin Cash, Litecoin and Ripple Daily Analysis – 25/02/18

    A promising start to Saturday’s session ended in yet another tumble for Bitcoin Cash, which has had a dire start to the year. Last weekend, the Bitcoin Cash rally kicked in late Saturday and came to an end in just a few hours, with Bitcoin Cash hitting a weekend high $1,630, an intraday gain of 7.77%, before tumbling to $1,392.3 just a few hours later. This Saturday’s moves were certainly shallower, Bitcoin Cash moving to a Saturday high $1,298.9, an intraday gain of 3.75%, before falling to a low $1,129.4.

  • Trump officials fight eviction from Panama hotel they manage
    Finance
    Associated Press

    Trump officials fight eviction from Panama hotel they manage

    One of President Donald Trump's family businesses is battling an effort to physically evict its team of executives from a luxury hotel in Panama where they manage operations, and police have been called to keep the peace, The Associated Press has learned. Witnesses told the AP they saw Trump's executives carrying files to a room for shredding. Representatives of the hotel owners' association formally sought to fire Trump's management team Thursday by hand-delivering termination notices to them at the Trump International Hotel and Tower, according to a Panamanian legal complaint filed by Orestes Fintiklis, who controls 202 of the property's 369 hotel units.

  • New tax scam can cause entire refund to vanish
    World
    KGO – San Francisco

    New tax scam can cause entire refund to vanish

    The IRS told the I-Team that people are being targeted by scams from all directions. Not only are there fake IRS calls, but there are new tax scams gaining popularity, including one where your entire tax return can vanish.

  • These Companies Are Sticking By The NRA
    Business
    HuffPost

    These Companies Are Sticking By The NRA

    NRA officials have gone on the attack to rail against the “politicization” of a tragedy, and going so far as to suggest that members of the media “love mass shootings” because of the ratings they supposedly bring. Enterprise Holdings, which operates the rental car brands Enterprise, National and Alamo, says it will end its discount program for NRA members next month, along with Avis and Budget.

  • Why Energy Stocks Sank in Trump's First Year in Office
    Business
    Motley Fool

    Why Energy Stocks Sank in Trump's First Year in Office

    From election day to inauguration day, energy stocks were on fire, with the average one in the S&P 500 rallying more than 7% on the hope that the pro-energy Trump Administration would eliminate some of the regulatory burdens that had been holding the industry back. Many factors played a role in driving energy stocks lower since Inauguration Day, most unrelated to presidential policy changes.

  • Retiring at 62 vs. 70: Pros and Cons
    Lifestyle
    Motley Fool

    Retiring at 62 vs. 70: Pros and Cons

    When most people think of retirement planning, they think about how much money they need to save. Social Security benefits play a major role in deciding your retirement age, though it's important to remember that claiming benefits and actually retiring don't always go hand in hand. The earliest you can claim Social Security benefits is age 62, but you'll receive a cut in benefits for every month you claim before your full retirement age (FRA), which is between 65 and 67, depending on the year you were born.

  • This Growth Stock Looks Like an Incredible Bargain After Getting Pummeled This Week
    Business
    Motley Fool

    This Growth Stock Looks Like an Incredible Bargain After Getting Pummeled This Week

    This week was a rough one for U.S. oil and gas giant Devon Energy (NYSE: DVN). Devon Energy's stock might be down now, but the recovery looks to be just ahead. Two related factors drove Devon Energy's sell-off this week.

  • 3 Cheap Dividend Stocks That Helped Warren Buffett Earn $3.7 Billion in Dividends in 2017
    Business
    Insider Monkey

    3 Cheap Dividend Stocks That Helped Warren Buffett Earn $3.7 Billion in Dividends in 2017

    Warren Buffett, the revered billionaire investor and Chairman and CEO of $500 billion holding company Berkshire Hathaway, just released his annual shareholder letter in which he discussed a number of intriguing topics. Perhaps the most noteworthy one was the revelation that Republican tax cuts contributed $29 billion to Berkshire Hathaway Inc. (NYSE:BRK.A)‘s bottom-line last year. That clearly proved irksome to Buffett, who supported Hillary Clinton during the 2016 Presidential Elections and was not fond of the idea of tax cuts for the wealthy. As Buffett made clear in the letter, the windfall “did not come from anything we accomplished at Berkshire.” The letter also revealed that Berkshire earned

  • America's Nightmare Flu Season Is Finally Coming to an End
    Business
    Fortune

    America's Nightmare Flu Season Is Finally Coming to an End

    The flu is on its way out. While still at epidemic levels, the historically bad 2017-2018 season has finally started to subside. Deaths caused by pneumonia and influenza fell to 9.5 percent of all fatalities across the country during the week ended Feb. 3, according to the Centers for Disease Control and Prevention’s most recent data.

  • Democrats distance themselves from Nancy Pelosi
    Politics
    Fox Business Videos

    Democrats distance themselves from Nancy Pelosi

    Former President George W. Bush Deputy Assistant Brad Blakeman discusses why Democrats are starting to disengage from Senate Minority Leader Nancy Pelosi.

  • Here's How Much Bitcoin Elon Musk Owns
    Business
    Fortune

    Here's How Much Bitcoin Elon Musk Owns

    Musk revealed this week on Twitter how much Bitcoin he owns—and it’s not much. Musk shed light on his bitcoin ownership in response to a question from a Twitter follower asking why there were so many bots impersonating him to push cryptocurrency scams. “What’s with all the ETH spam?” the Twitter user asked, referring to the cryptocurrency Ethereum.

  • Latest Mueller indictment spells trouble for bankers, too
    Finance
    Associated Press

    Latest Mueller indictment spells trouble for bankers, too

    Recently filed federal charges against President Donald Trump's ex-campaign chairman Paul Manafort could also pose legal and regulatory risks for the banks that loaned him millions of dollars against his New York real estate in recent years. The most serious exposure may be for a Rhode Island-based bank that employed a "conspirator" in Manafort's scheme to obtain a loan he couldn't afford, according to the 32-count new indictment unsealed this week. Dubbed "Lender B" in court papers, Citizens Bank not only lent Manafort $3.4 million based off of fraudulent documents but, in another case, appeared to help Manafort avoid being caught by sending back a crudely falsified financial statement that had been sent to them from a Manafort associate, according to federal prosecutors.

  • 3 Reasons Traditional IRAs Are Better Than Roth IRAs
    Business
    Motley Fool

    3 Reasons Traditional IRAs Are Better Than Roth IRAs

    Saving for retirement is important, and someone making the most of the savings they're able to set aside will make a huge difference in how comfortable their retirement is. The federal government offers many tax-favored retirement savings vehicles, and one of the most popular is the IRA. One question millions of people face every year is whether to use a traditional or Roth IRA.

  • Best Dividend Stocks This Month
    Business
    Simply Wall St.

    Best Dividend Stocks This Month

    Valero Energy is one of the top dividend stocks I think are worth considering today. A large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over time. If you’re a long term investor, these high-performing top dividend stocks can boost your monthly portfolio income.

  • Why Nvidia (NVDA) Stock Is the Cheapest It's Been in Nearly a Year
    Finance
    Zacks

    Why Nvidia (NVDA) Stock Is the Cheapest It's Been in Nearly a Year

    It is no secret that Nvidia NVDA is one of Wall Street’s most popular stocks. The graphics chip maker is a dominant force in the global gaming industry, and its tireless investments in self-driving cars, machine learning, and artificial intelligence all but guarantee the company a spot among the tech industry’s leaders for years to come. Nvidia’s leadership and innovation have also led to a massive surge in the company’s stock.

  • Trump Said to Weigh 'Red Flag' Orders to Take Guns Away Quickly
    Politics
    Time

    Trump Said to Weigh 'Red Flag' Orders to Take Guns Away Quickly

    The White House is considering the idea of using restraining orders to take firearms away from people considered dangerous as part of its response to last week’s massacre at a Florida high school, two people familiar with the matter said. Under extreme risk protection orders, which are also known as red flag laws or gun violence restraining orders, firearms can be confiscated from people found to be at risk. The White House is studying an Indiana version of the law, and is considering other measures as well, according to the people, who requested anonymity to discuss policy deliberations.

  • Adam Schiff's Memo Has Been Released. Here's What It Says
    Politics
    Time

    Adam Schiff's Memo Has Been Released. Here's What It Says

    Democrats on the the House Intelligence Committee on Saturday released a memo prepared as a counter to the one overseen by the committee’s chairman Devin Nunes that was publicized earlier this month. Overseen by Rep. Adam Schiff, the ranking Democrat on the committee, the memo from the Democrats attempts to contextualize the Nunes memo, which argued that the FBI displayed bias in obtaining a FISA warrant for former Trump campaign adviser Carter Page. That memo alleges that the FBI failed to disclose Christopher Steele, who compiled the notorious Steele dossier, was working for Fusion GPS or the firm’s founder Glenn Simpson, and that Deputy FBI Director Andrew McCabe — who is stepping down —said the FBI would not have sought a warrant without the dossier.

  • These 3 Dividend Stocks Offer Shares at a Discount
    Business
    Motley Fool

    These 3 Dividend Stocks Offer Shares at a Discount

    Dividend stocks can help investors benefit from the power of compounding. By reinvesting dividend payments to purchase additional shares of stock, you'll see the amount of income you receive grow over time, building on itself and creating a positive-feedback loop that can eventually produce huge amounts of income. In particular, Aqua America (NYSE: WTR), Franco-Nevada (NYSE: FNV), and Student Transportation (NASDAQ: STB) are three stocks that you can buy more cheaply through dividend reinvestment than you'll get on the open market.

  • President Trump Still Hasn't Forgiven John McCain for Killing Obamacare Repeal
    Politics
    Time

    President Trump Still Hasn't Forgiven John McCain for Killing Obamacare Repeal

    President Donald Trump has again blasted Sen. John McCain for voting against the repeal and replacement of the Affordable Care Act last summer — but did not once call him by name. “We’re having tremendous plans coming out now, healthcare plans, at a fraction of the cost, that are much better than Obamacare,” Trump said Friday at the Conservative Political Action Conference. “Remember — one person walked into a room when he was supposed to go this way,” Trump added, giving a thumbs up sign, “and he walked in and went this way [thumbs down] and everyone said, ‘What happened?

  • US asks judge to approve seizure of Pharma Bro's assets
    Finance
    Associated Press

    US asks judge to approve seizure of Pharma Bro's assets

    NEW YORK (AP) — "Pharma Bro" Martin Shkreli appeared in court Friday for the first time since a judge locked him up for his online antics, and the brash former pharmaceutical CEO had a new look since his bail was revoked in September: a scruffy beard that made his appearance less boyish. "Under the circumstances, I think he's doing remarkably well," his attorney, Ben Brafman, told reporters when asked about his client's stint in a fortress-like federal jail in Brooklyn. U.S. District Judge Kiyo Matsumoto didn't immediately rule on the government's demand that Shkreli should have to forfeit $7.3 million in assets, including a one-of-a-kind Wu-Tang Clan "Once Upon a Time in Shaolin" album that he has boasted he bought for $2 million.